Chas Waring’s Post

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navallier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navallier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Wall Street analysts are watching these stocks on Thursday - https://lnkd.in/diPCnZtw Here are Thursday's biggest calls on Wall Street: Goldman Sachs initiates Apellis Pharmaceuticals as buy Goldman initiated the biotech company with a buy and says it sees "continued execution." "APLS is a commercial biopharmaceutical company developing therapies through inhibition of complement at the level of C3, with approved assets Syfovre, an intravitreal injection for geographic atrophy (GA), a form of age-related macular degeneration that causes vision loss, and Empaveli in paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder." HSBC initiates Tesla as reduce HSBC said in its initiation of Tesla that the stock's valuation is too rich. "Tesla is more than a very expensive auto company; its ambition is to be an innovator, which underpins the valuation." Barclays upgrades Kellanova to equal weight from underweight Barclays said it sees top-line growth for the company. "With the spin of its North America cereal business (WK Kellogg, ticker KLG) now firmly in the rear view, we are upgrading K (now known as Kellanova vs Kellogg previously) to Equal Weight from Underweight." Wolfe upgrades Spirit AeroSystems to buy outperform from peer perform Wolfe said shares of the aersopace company are derisked. "We upgrade shares of SPR to Outperform from Peer Perform following a cascade of derisking that should set the stock up to work on the expected production upcycle." JPMorgan upgrades Montrose to overweight from neutral JPMorgan said in its upgrade of the environmental services company that shares are "compelling." "We are reducing our Dec-24 price target to $41 to reflect a lower target multiple in a higher rate environment; however, we are upgrading the stock to Overweight from Neutral as we see the current stock valuation as very compelling." Bank of America reiterates Disney as buy Bank of America said it's standing by its buy rating after Wednesday's earnings report. "DIS' F4Q results were mixed with revenues below our forecast while operating income was above our expectations." Goldman Sachs reiterates Arm as overweight Goldman said it's sticking with its buy rating after the stock's earnings report on Wednesday. "That said, we are reiterating our Buy rating on ARM with an updated 12-month price target of $65 (up from $62 prior) and, as such, would recommend investors to take advantage of any pullback to add to or initiate positions." Goldman Sachs reiterates Instacart as buy Goldman said it's sticking with its buy rating on the grocery delivery company after Instacart's earnings report on Wednesday. "Shorter term, we expect investors will remain focused on elements of consumer demand, competitive intensity, the broader offline to online grocery industry shifts and the mix of stock buyback aut

Last week Eli Lilly & Co. stock gapped up +11.43% & continued higher, driven by trading volumes that were 97.1% higher than the prior year's average volume (5,909,900 vs. 2,998,360). As they're still making new 52-week highs with limited support in the window created by the gap (only the 10 Day Moving Average), it's important to have an understanding of market participant sentiment at the price levels they've traded at in recent history. Check out this Price:Volume Sentiment Analysis to gain insight into how market participants may value LLY shares at different price levels in an environment with limited support touch-points! #technicalanalysis #stocks #stockmarket #pharmaceutical https://lnkd.in/e47gEuyY

Amgen's stock performed well in the third quarter, while solar shares were unsuccessful. October 02, 2023: Amgen Inc. (AMGN) won in the third quarter of 2023, with its stock price rising by over 10%. However, many solar stocks struggled during the quarter, with some losing over 20% of their value. https://lnkd.in/gxMdkcdu #BreakingNews #news #theleadersmagazine #trendingnow #trendingnews #BreakingNews #BREAKING #dailynews

Eli Lilly stock shoots up into record territory after earnings beat, a big increase in the full-year outlook Shares of Eli Lilly & Co. shot up 9.0% into record territory in premarket trading Tuesday, after the drug giant reported second-quarter profit and revenue that climbed above expectations and provided a big boost its full-year outlook, as results were helped by the $579 million received from the sale of rights for Baqsimi. Net income jumped to $1.76 billion, or $1.95 a share, from $952.5 million, or $1.05 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.11 beat the FactSet consensus of $1.98. Revenue grew 28.1% to $8.31 billion, well above the FactSet consensus of $7.58 billion. Volume increased 29%, driven by growth in Mounjaro, Verzenio, Jardiance and Taltz, partially offset by lower volume from Alimta due to the loss of exclusivity. For 2023, the company raised its guidance ranges for adjusted EPS to $9.70 to $9.90 from $8.65 to $8.85 and for revenue to $33.4 billion to $33.9 billion from $31.2 billion to $31.7 billion. The stock, which was on track to open well above its June 30 record close of $468.98, has rallied 24.1% year to date through Monday while the S&P 500 has advanced 17.7%. https://lnkd.in/gyyDBDG6

Is NeuBase (USA Stocks:NBSE) outlook still optimistic?: NeuBase Therapeutics (NBSE) is currently trading at $1.03, which is marginally above its 200-day moving average of $0.99. The stock has seen a recent decline, with a price percent change of -3.74%, but given its position above the 200-day MA, it could be poised for a rebound. However, investors should be aware of the company's financials, particularly its income before tax which shows a loss of $33.8 million. This indicates a challenging financial position, which could impact the stock's performance. On the brighter side, Wall Street's target price for the stock stands at a staggering $140, suggesting significant potential upside if the company can turn its fortunes around. Important Takeaways NeuBase Therapeutics stock holds an average rating of 'Hold' from one analyst. This consensus may be based on technical analysis, which typically uses price momentum, patterns, and trends from historical prices. The goal is to identify signals based on market sentiment, which reflects investors' perception of NeuBase's future value. Let's delve into some aspects of NeuBase's technical analysis.Continue To Read... https://lnkd.in/gg_q-ZDq